NCI must make a bigger investment in new cancer therapies and expand the clinical trials system that tests them, the institute’s Acting Director Douglas Lowy said in his remarks at the American Society of Clinical Oncology annual meeting June 4.
NCI has renewed MUSC Hollings Cancer Center’s five-year Cancer Center Support Grant, with an overall rating of “outstanding.”
